乌司他丁联合奥曲肽治疗重症急性胰腺炎患者的临床效果  

Clinical efficacy of Ulinastatin combined with Octreotide in the treatment of patients with severe acute pancreatitis

作　　者：刘攀 张其强 张倩 LIU Pan;ZHANG Qiqiang;ZHANG Qian(Department of Critical Care Medicine Third District,Linyi Central Hospital,Linyi,Shandong 276400,China)

机构地区：[1]临沂市中心医院重症医学科三区,山东临沂276400

出　　处：《医药前沿》2025年第10期39-42,共4页Journal of Frontiers of Medicine

摘　　要：目的分析重症急性胰腺炎(SAP)患者使用乌司他丁联合奥曲肽治疗的效果。方法回顾性分析临沂市中心医院2019年2月—2024年2月收治的SAP患者60例,按照治疗方法不同分为观察组和对照组,各30例。对照组采用醋酸奥曲肽注射液治疗,观察组在对照组用药基础上联合乌司他丁注射液治疗。比较两组临床疗效、症状缓解时间、免疫反应指标[免疫球蛋白(Ig)A、IgG、IgM]、氧化应激指标[谷胱甘肽过氧化物酶(GSH-Px)、超氧化物歧化酶(SOD)、丙二醛(MDA)、活性氧(ROS)]、炎症因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]和不良反应。结果治疗后,观察组总有效率和IgA、IgM、IgG、GSH、SOD水平高于对照组,MDA、ROS、IL-6、TNF-α、hs-CRP水平低于对照组,各项症状缓解时间短于对照组(P<0.05)。治疗期间,两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论乌司他丁联合奥曲肽治疗SAP效果显著,能促进患者症状缓解,提高免疫力,减轻氧化应激及炎症反应,且不增加不良反应。Objective To analyze the therapeutic efficacy of using Ulinastatin combined with Octreotide in the treatment of severe acute pancreatitis(SAP)patients.Methods A total of 60 SAP patients admitted to Linyi Central Hospital from February 2019 to February 2024 were retrospectively analyzed.According to different treatment methods,they were divided into observation group and control group,with 30 cases in each group.The control group was treated with Octreotide Acetate Injection,while the observation group received Ulinastatin Injection in addition to the control group's treatment.The clinical efficacy,symptom relief time,immune response indicators[immunoglobulin(Ig)A,IgG,IgM],oxidative stress indicators[glutathione peroxidase(GSH-Px),superoxide dismutase(SOD),malondialdehyde(MDA),reactive oxygen species(ROS)],inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),hypersensitive-C reactive protein(hs-CRP)],and adverse reactions were compared between the two groups.Results After treatment,the total effective rate and the levels of IgA,IgM,IgG,GSH and SOD in the observation group were higher than those in the control group,the levels of MDA,ROS,IL-6,TNF-αand hs-CRP were lower than those in the control group,and the remission time of each symptom was shorter than that in the control group(P<0.05).During the treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Ulinastatin combined with Octreotide is effective in treating SAP,promoting symptom relief,improving immunity,reduce oxidative stress and inflammatory response,without increasing adverse reactions.

关 键 词：重症急性胰腺炎 乌司他丁 奥曲肽 免疫球蛋白 谷胱甘肽过氧化物酶 白细胞介素-6 

分 类 号：R657[医药卫生—外科学]